Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.

Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: A dynamic hybrid residential threat detection method is disclosed. The method includes receiving, by a packet selector on a customer premises equipment (CPE), communication sessions and selecting and sending, by the packet selector, a predefined number of packets of the communication sessions to a CPE detection engine based on packet selection rules. The method also includes inspecting, by the CPE detection engine, the predefined number of packets of each communication session based on CPE detection rules that establish what type of inspection is to be performed by the CPE detection engine based at least in part on CPE resource constraints. The method further includes sending, by the packet selector, the predefined number of packets of at least some of the communication sessions to a cloud detection engine and blocking particular communication traffic on the CPE based on the inspection and/or an instruction from the cloud detection engine.

Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: A dynamic hybrid residential threat detection method is disclosed. The method includes receiving, by a packet selector on a customer premises equipment (CPE), communication sessions and selecting and sending, by the packet selector, a predefined number of packets of the communication sessions to a CPE detection engine based on packet selection rules. The method also includes inspecting, by the CPE detection engine, the predefined number of packets of each communication session based on CPE detection rules that establish what type of inspection is to be performed by the CPE detection engine based at least in part on CPE resource constraints. The method further includes sending, by the packet selector, the predefined number of packets of at least some of the communication sessions to a cloud detection engine and blocking particular communication traffic on the CPE based on the inspection and/or an instruction from the cloud detection engine.

Abstract: A dynamic cloud-based threat detection system is disclosed. The system comprises a network broker that receives communication sessions associated with communication device(s) via a network and selects and sends a predefined number of packets of each communication session to a detection based on packet selection rules. The communication device(s) comprises customer premises equipment (CPE) and/or a mobile communication device. The detection engine receives and inspects the predefined number of packets of each communication session and a governor that initiates blocking of particular communication traffic based on the inspection. The system also comprises a dynamic optimizer that monitors factor(s) and creates and sends updated packet rules to the network broker based on the monitoring. The network broker selects and sends a different predefined number of packets of each of a second plurality of communication sessions to the detection engine for inspection based on the updated packet selection rules.

Abstract: A display system for sensing a finger of a user applied to the display system includes a display panel; a sensor for sensing the finger; a sensing light source configured to emit a first light having a first wavelength W1; and a reflective polarizer disposed between the display panel and the sensor. For a substantially normally incident light, an optical transmittance of the reflective polarizer versus wavelength for a first polarization state has a band edge such that for a first wavelength range extending from a smaller wavelength L1 to a greater wavelength L2 and including W1, where 30 nm?L2?L1?50 nm and L1 is greater than and within about 20 nm of a wavelength L3 corresponding to an optical transmittance of about 50% along the band edge, the optical transmittance has an average of greater than about 75%.

Abstract: An optically diffusive film (200) includes a plurality of particles (10) dispersed in a binder (20). The particles (10) and the binder (20) have respective indices n1b and n2b along a same in-plane block-direction of the optically diffusive film (200), and respective indices n1p and n2p along an in-plane pass-direction orthogonal to the block-direction, such that for at least a first wavelength in a first wavelength range extending from about 400 nm to about 1000 nm: a magnitude of a difference between n1b and n2b is greater than about 0.05; and a magnitude of a difference between n1p and n2p is less than about 0.05. For substantially normally incident light and for at least the first wavelength, the optically diffusive film (200) may be more optically diffuse for a light polarized along a block-direction (b) and less optically diffusive for light polarized along an orthogonal pass-direction (p).

Abstract: A method of dynamic residential threat detection is disclosed. The method includes a packet selection component on a customer premises equipment (CPE) sending a predefined number of packets of each of a plurality of communication sessions to a detection engine based on packet selection rules. The method also includes the detection engine on the CPE receiving and inspecting the predefined number of packets. The method further includes a dynamic optimizing component on the CPE monitoring one or more factors and creating and sending updated packet selection rules based on the monitored factor(s) to the packet selection component. The method additionally comprises the packet selection component sending a different predefined number of packets of each of a second plurality of communication sessions to the detection engine based on the updated packet selection rules. The method further includes the detection engine receiving and inspecting the different predefined number of packets.

Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Formulated and/or co-formulated nanocarriers comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the nanocarriers are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a nanocarrier (e.g., LNP or SLNP) to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.

Abstract: Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.

Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.